Fundamentals-based quality & risk · not a recommendation
Krebs Biochemicals & Industries Ltd scores 18/100 (Avoid) on the Orion Score — poor business quality (8), poor growth (8) and moderate balance-sheet safety (52). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
50/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹6.81 | ₹-2.34 | -35.7% | ₹-1.09 |
| Q3 2026 | ₹7.27 | ₹-3.13 | -18.4% | ₹-1.45 |
| Q2 2026 | ₹4.17 | ₹-6.14 | -106.0% | ₹-2.85 |
| Q1 2026 | ₹5.48 | ₹-5.32 | -67.3% | ₹-2.47 |
| Q4 2025 | ₹6.1 | ₹-8.27 | -114.4% | ₹-3.83 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹43.31 | ₹-26.94 | ₹-14.32 | -50.1% |
| FY 2024 | ₹50.42 | ₹-19.73 | ₹-8.28 | -30.7% |
| FY 2023 | ₹52.13 | ₹-24.69 | ₹-15.16 | -42.1% |
| FY 2022 | ₹59.7 | ₹-44.53 | ₹-32.85 | -66.2% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| KREBSBIO ★ | ₹140 Cr | — | -23.66% | — | — | -35.73% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹169.04 | ₹178.17 | ₹174.98 | ₹189.81 |
| Equity | ₹-146.24 | ₹-119.22 | ₹-99.46 | ₹-75.09 |
| Total Debt | ₹212.21 | ₹238.68 | ₹228.37 | ₹188.1 |
| Cash | ₹0.14 | ₹0.07 | ₹0.02 | ₹0.03 |
| Net Debt | ₹212.07 | ₹193.61 | ₹183.35 | ₹143.07 |
| Working Capital | ₹-93.27 | ₹-44.39 | ₹-33.04 | ₹-42.57 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 77.55% ↑ | 0% ↓ | 0% | 22.45% ↓ |
| Q3 FY2026 | 72.74% | 0.5% | — | 26.76% |
| Q2 FY2026 | 72.74% | 0.5% | — | 26.76% |
| Q1 FY2026 | 72.74% | 0.5% | — | 26.76% ↑ |
| Q4 FY2025 | 72.74% | 0.5% | — | 26.75% ↓ |
| Q3 FY2025 | 72.74% | 0.5% | — | 26.76% |
| Q2 FY2025 | 72.74% | 0.5% | — | 26.76% ↑ |
| Q1 FY2025 | 72.74% | 0.5% | — | 26.75% |
No recent corporate actions
Ask: "Is Krebs Biochemicals & Industries Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Krebs Biochemicals & Industries Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE268B01013. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.